CURLF News

CURLF's hostile Aurora bid adds uncertainty as revenues recover, but margin pressure, rising costs and intense competition keep investors cautious.

Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks and earnings pressures.

TerrAscend's improving revenues, margins and cash flow support its recovery, while debt, competition and regulatory uncertainty remain key concerns.

Tilray's revenues and EBITDA are growing, but weak margins, negative cash flow and competition raise questions about its next move.

Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Cresco's 10% monthly rally reflects stronger revenues, organic growth and margins, but competition and normalization risks cloud the outlook.

The mean of analysts' price targets for Curaleaf Holdings, Inc. (CURLF) points to a 43.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Verano's rally follows strong Q2 results, but margin pressure and wider 2026 losses keep the stock in wait-and-watch mode.

In a statement on Monday, Curaleaf rejected Aurora’s assertions of inaccuracies in its unsolicited bid and accused the Canadian firm of using selective metrics to deflect from years of underperformance.